Acurx holders re-elect Luci, Dean as Class II directors; ratify CohnReznick for FY2026

Acurx Pharmaceuticals, Inc.

Annual meeting held Oct 16, 2026; record date Aug 20, 2026 with 5,471,297 shares outstanding; quorum of 2,890,899 shares, or 52.83%.
David P. Luci re-elected with 1,187,323 votes for and 73,804 withheld; Jack H. Dean with 1,203,310 for and 57,817 withheld.
Both Class II directors serve three-year terms expiring in 2029; broker non-votes totaled 1,629,772 on the director proposals.
Stockholders ratified CohnReznick LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026: 2,877,193 for, 8,473 against, 5,233 abstentions.
Two proposals were submitted, per the definitive proxy statement filed Sept 1, 2026; no other business reported.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.